The call aims to identify and fund projects focused on validation of potential small molecule or antibody targets in pathways important in the development or progression of musculoskeletal conditions. The call to UK-based academic researchers seeks to fund target validation and proof of concept studies prior to initiating a full scale drug discovery project.
The call aims to identify and fund either one or two projects focused on potential small molecule or antibody targets. It is targeted at academic researchers and seeks to fund target validation and proof of concept studies prior to initiating a full scale drug discovery project.
The humanized antibody is now being developed by MSD, known as Merck in the US and Canada. Lambrolizumab is an investigational antibody therapy targeting Programmed Death receptor (PD-1) that is currently being evaluated for the treatment of patients with advanced melanoma, and other tumor types. MSD recently announced lambrolizumab has been designated as a Breakthrough Therapy for the treatment of patients with advanced melanoma by the U.S. Food and Drug Administration (FDA).
The primary focus of the exchange program is to strengthen knowledge transfer offices in universities, public research organisations, and hospitals, and to promote trans-national collaboration between industry and academia in the health sector. MRC Technology will provide participating Technology Transfer Officers with a clearer understanding of processes and priorities, and a unique insight into the organisation’s business culture and approach.
The initiative will focus on identification of novel druggable targets in the field of small molecules and antibodies, and collaborating to fast track those targets through drug discovery to create potent and selective novel therapeutics. It brings together EMBLEM’s experience in supporting academics in one of the world’s leading locations for scientific research, with MRC Technology’s dedicated expertise in translating novel biology targets into lead stage therapeutic assets.
MRC Technology's Director of Drug Discovery, Justin Bryans, is quoted in a Nature Biotechnology article about the…
The on-going collaboration between MRC Technology and the Institute of Biophysics, Chinese Academy of Sciences (IBP CAS) aims to develop the antibody as a cancer therapeutic.
MRC Technology's CEO, Dave Tapolczay, gave evidence to the UK House of Commons Science and Technology Committee…
The call aims to to fast-track the discovery and development of novel drugs to slow, stop or reverse progression in MS or treat MS symptoms. The call to academic researchers seeks to fund further validation of small molecule and antibody targets prior to initiating a full scale drug discovery project to produce ‘drug-like’ molecules or therapeutic antibodies that have the potential to become therapies.